摘要
目的中性粒细胞明胶酶相关脂质运载蛋白(NGAL),也被称为脂质运载蛋白2(LCN2)是一种与代谢综合征及血管生成相关的重要脂肪因子。通过检测伴或不伴糖尿病性视网膜病变(DR)的2型糖尿病(T2DM)患者血清中LCN2的表达,探讨其与DR的关系。方法研究纳入85例T2DM患者及20例正常健康人(对照组)。在T2DM患者中,30例患有增生性糖尿病视网膜病变(PDR),29例患有非增生性糖尿病视网膜病变(NPDR),26例无视网膜病变。采用酶联免疫吸附法(ELISA)检测病患者血清中LCN2的水平,统计分析和比较各组之间的差异。结果 LCN2在PDR、NPDR、无DR的T2DM组患者中的水平分别是(6.63±0.97)、(6.07±0.75)、(5.43±0.97)μg/l,3组之间比较有统计学差异(P<0.05)。T2DM组的LCN2水平高于对照组(4.76±1.08μg/l)(P<0.05)。简单线性回归分析提示,在T2DM患者中,血清LCN2水平与糖尿病病程,体重指数(BMI),血清甘油三酯,总胆固醇有关,与年龄、收缩压、舒张压无关。逐步回归分析提示,BMI与血清LCN2水平显著相关(P=0.028)。结论在NPDR和PDR组中,血清LCN2水平明显升高,且PDR组明显高于NPDR组,推测LCN2可能在DR的发生、发展中起着作用。
Objective To examine the expression of NGAL/lipocalin-2(LCN2),a kind of adipokines associated with metabolic syndrome and angiogenesis,in type 2 diabetes( T2 DM) patients with or without diabetic retinopathy( DR)and to investigate its relationship with the occurrence and development of DR. Methods A total of 85 T2 DM patients and20 healthy subjects( control group) were enrolled. Of the T2 DM patients,30 had proliferative diabetic retinopathy( PDR group),29 had non-proliferative retinopathy( NPDR group) and 26 had no retinopathy( T2 DM group). LCN2 levels in the serum were detected by enzyme-linked immunosorbent assay( ELISA) and the difference among these groups was analyzed statistically. Results LNC2 levels in PDR,NPDR and T2 DM groups were 6. 63 ± 0. 97 μg/l,6. 07 ± 0. 75? g/l and 5. 43 ± 0. 97 μg/l,with significant difference across the three groups( P 0. 05). LCN2 level in T2 DM group was higher than the control group(4. 76 ± 1. 08 μg/l)( P 0. 05). Simple linear regression showed that serum LCN2 was correlated with duration of diabetes,body mass index( BMI),serum triglycerides,total cholesterol,and not correlated with age,systolic and diastolic blood pressure in all T2 DM patients. Stepwise regression analysis showed that BMI was significantly associated with serum LCN2( P = 0. 028). Conclusions Serum LCN2 level was significantly increased in the NPDR and PDR group and was more in PDR than NPDR group. LCN2 might be involved in the development and progress of DR.
作者
陈萌
张英辉
李蓉
张玉荣
Chen Meng;Zhang Yinghui;Li Rong;Zhang Yurong;Zhang Ying- hui;Li Rong;Zhang Yurong(Department of Ophthalmology, 3201 Hospital, Xi'an Jiaotong University, Hanzhong , Shaanxi 72300;Department of Ophthalmology, Xi'an XD Group Hospital, Xi' an, Shaanxi 710077;Department of Ophthabnology, The First Affiliated Hospital, Xi'an Medical Unversity, Xi' an, Shaanxi 710077;Department of Phar- macy, The First Affiliated Hospital, Xi'an Medical University, Xi ' an, Shaanxi 710077, China)
出处
《临床眼科杂志》
2018年第2期149-153,共5页
Journal of Clinical Ophthalmology
基金
西安市科技局基金(SF1608)